PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.59M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-10.04%
Negative revenue growth while AVGO stands at 4.72%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-13.64%
Negative gross profit growth while AVGO is at 3.94%. Joel Greenblatt would examine cost competitiveness or demand decline.
-18.51%
Negative EBIT growth while AVGO is at 9.96%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-18.97%
Negative operating income growth while AVGO is at 9.96%. Joel Greenblatt would press for urgent turnaround measures.
-19.78%
Negative net income growth while AVGO stands at 6.69%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-20.21%
Negative EPS growth while AVGO is at 6.25%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-19.46%
Negative diluted EPS growth while AVGO is at 7.79%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
-0.11%
Reduced diluted shares while AVGO is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
4.88%
Dividend growth above 1.5x AVGO's 0.16%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-0.67%
Negative OCF growth while AVGO is at 2.31%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
75.57%
FCF growth above 1.5x AVGO's 2.74%. David Dodd would verify if the firm’s strategic investments yield superior returns.
61.04%
10Y revenue/share CAGR under 50% of AVGO's 656.30%. Michael Burry would suspect a lasting competitive disadvantage.
15.12%
5Y revenue/share CAGR under 50% of AVGO's 70.33%. Michael Burry would suspect a significant competitive gap or product weakness.
1.24%
3Y revenue/share CAGR under 50% of AVGO's 41.30%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
91.92%
10Y OCF/share CAGR under 50% of AVGO's 1267.52%. Michael Burry would worry about a persistent underperformance in cash creation.
-5.86%
Negative 5Y OCF/share CAGR while AVGO is at 82.78%. Joel Greenblatt would question the firm’s operational model or cost structure.
-8.36%
Negative 3Y OCF/share CAGR while AVGO stands at 41.77%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
220.89%
Below 50% of AVGO's 1130.29%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
16.14%
Below 50% of AVGO's 215.29%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
-17.80%
Negative 3Y CAGR while AVGO is 161.66%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
87.00%
Below 50% of AVGO's 399.11%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
97.18%
Positive 5Y equity/share CAGR while AVGO is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
86.15%
Positive short-term equity growth while AVGO is negative. John Neff sees a strong advantage in near-term net worth buildup.
333.29%
Below 50% of AVGO's 1905.83%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
68.41%
Below 50% of AVGO's 162.71%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
27.57%
3Y dividend/share CAGR at 75-90% of AVGO's 34.18%. Bill Ackman wants overhead or revenue enhancements to match competitor's dividend growth.
-9.56%
Firm’s AR is declining while AVGO shows 8.24%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
2.33%
Inventory growth well above AVGO's 3.04%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
2.24%
Asset growth 1.25-1.5x AVGO's 1.77%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
1.60%
Under 50% of AVGO's 8.65%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
5.05%
We have some new debt while AVGO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-2.34%
Our R&D shrinks while AVGO invests at 2.21%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-3.10%
We cut SG&A while AVGO invests at 7.73%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.